Issue Focuses on Companies and Trends in the Medical Supply and
Device Industry
SAN DIEGO, Jan. 22 /PRNewswire-FirstCall/ --
Protein Polymer Technologies (OTC Bulletin Board: PPTI), a Company focused on
the development of high performance bioactive devices designed for improved
surgical outcomes, announced today that its president and CEO, Dr. J. Thomas
Parmeter, was recently featured in The Wall Street Transcript's 190-page
"Medical Supplies & Devices" issue. Published on January 12, 2004, the
extensive report contains an analyst roundtable forum, individual analyst
interviews, and in-depth interviews with executives from 19 publicly traded
companies in the medical supply and device industry. The complete interview
with Dr. Parmeter will be available next week on PPTI's website, http://www.ppti.com.
Topics discussed during Dr. Parmeter's interview include:
* PPTI background including two products in human clinicals, a third to
begin human clinicals shortly, new products in the pipeline, all based
on platform technology covered by 25 U.S. patents
* How PPTI's urethral bulking agent should offer an alternative to
surgery in the large and growing market opportunity for the treatment
of female stress urinary incontinence
* Why PPTI's injectable hydrogel technology for the treatment of dermal
contour deficiencies should provide longer lasting results in the
rapidly expanding market for cosmetic facial treatments, and how the
product is complementary to Botox(R)
* PPTI's adhesive hydrogel technology for use in spinal disc repair, and
the company's strategic relationship with Spine Wave which it helped
establish to develop and market new technology for orthopedic
applications
* Key personnel and strategy for growth
"Showcasing PPTI and our technology in The Wall Street Transcript's
'Medical Supplies & Devices' issue provides an ideal opportunity for PPTI to
communicate our core messages to a very targeted and important audience. In
particular, the investment community should find my interview to be a valuable
resource when making decisions about PPTI and the markets that we serve,"
stated J. Thomas Parmeter, Ph.D., President and CEO of Protein Polymer
Technologies.
About Protein Polymer Technologies
Protein Polymer Technologies, Inc., is a San Diego-based company focused
on developing bioactive devices to improve medical and surgical outcomes.
From its inception in 1988, PPTI has been a pioneer in protein design and
synthesis, creating an extensive portfolio of proprietary biomaterials for use
in the development of bioactive devices. These genetically engineered
biomaterials are high molecular weight proteins, processed into products with
physical and biological characteristics tailored to specific clinical
performance requirements. Targeted products include urethral bulking agents
for the treatment of stress urinary incontinence, dermal augmentation products
for cosmetic and reconstructive surgery, surgical adhesives and sealants,
scaffolds for wound healing and tissue engineering, and depots for local drug
delivery. To date, PPTI has been issued 25 U.S. Patents on its core
technology with corresponding issued and pending patents in key international
markets.
Safe Harbor
This press release contains forward-looking statements that are based on
management's views and expectations. Actual results could differ materially
from those expressed here; further, the Company is not obligated to comment
specifically on those differences. Risks associated with the Company's
activities include raising adequate capital to continue operations scientific
and product development uncertainties, competitive products and approaches,
continuing collaborative partnership interest and funding, regulatory testing
and approvals, and manufacturing scale up. The reader is encouraged to refer
to the Company's 2002 Annual Report Form 10-KSB, and other recent filings with
the Securities and Exchange Commission, copies of which are available from the
Company, to further ascertain the risks associated with the above statements.
SOURCE Protein Polymer Technologies, Inc.
 back to top
Related links:
http://www.ppti.com
CONTACT:
J. Thomas Parmeter, Ph.D., President, Chief
Executive Officer of Protein Polymer Technologies,
+1-858-558-6064; or investors, Jill Meleski of The Ruth Group,
+1-646-536-7032
|
